BioSapien

From Philosophy to Cancer: The Unusual Story of Khatija Ali and BioSapien adsmehub.ae/en/explore/post-…

Exciting news! 🚀 BioSapien, a cutting-edge biotech company focused on localized drug delivery, has successfully raised $5.5 million in pre-Series A funding! Their flagship product, MediChip™, is a 3D-printed, slow-release drug delivery platform designed to treat cancer locally, minimizing systemic side effects while increasing drug efficacy. This innovative technology has the potential to revolutionize cancer treatment, providing patients with better quality of life, fewer side effects, and reducing the need for invasive surgeries. With this new funding, BioSapien will accelerate its clinical trials in the UAE, beginning patient enrolment in Abu Dhabi in Q2 2025. The company is also focused on expanding product development, manufacturing, and talent acquisition to further enhance their life-changing platform. We are proud to support BioSapien in their mission to redefine cancer treatment, and look forward to the impact this groundbreaking technology will have on patients in the UAE and beyond!